196 related articles for article (PubMed ID: 37289448)
1. Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.
Woo SJ; Bradvica M; Vajas A; Sagong M; Ernest J; Studnicka J; Veith M; Wylegala E; Patel S; Yun C; Orski M; Astakhov S; Tóth-Molnár E; Csutak A; Enyedi L; Kim T; Oh I; Jang H; Sadda SR
JAMA Ophthalmol; 2023 Jul; 141(7):668-676. PubMed ID: 37289448
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Woo SJ; Veith M; Hamouz J; Ernest J; Zalewski D; Studnicka J; Vajas A; Papp A; Gabor V; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Bressler NM
JAMA Ophthalmol; 2021 Jan; 139(1):68-76. PubMed ID: 33211076
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial.
Woo SJ; Sadda SR; Bradvica M; Vajas A; Sagong M; Ernest J; Studnička J; Veith M; Wylegala E; Patel S; Yun C; Orski M; Astakhov S; Tóth-Molnár E; Csutak A; Enyedi L; Choi W; Oh I; Jang H
BMJ Open Ophthalmol; 2023 Dec; 8(1):. PubMed ID: 38114333
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity With Ranibizumab Biosimilar SB11 (Byooviz) and Reference Product Lucentis and Association With Efficacy, Safety, and Pharmacokinetics: A Post Hoc Analysis of a Phase 3 Randomized Clinical Trial.
Bressler NM; Kim T; Oh I; Russo P; Kim MY; Woo SJ
JAMA Ophthalmol; 2023 Feb; 141(2):117-127. PubMed ID: 36520462
[TBL] [Abstract][Full Text] [Related]
5. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
Bressler NM; Veith M; Hamouz J; Ernest J; Zalewski D; Studnička J; Vajas A; Papp A; Vogt G; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Oh I; Jeong H; Kim MY; Woo SJ
Br J Ophthalmol; 2023 Mar; 107(3):384-391. PubMed ID: 34656987
[TBL] [Abstract][Full Text] [Related]
7. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
Holz FG; Oleksy P; Ricci F; Kaiser PK; Kiefer J; Schmitz-Valckenberg S;
Ophthalmology; 2022 Jan; 129(1):54-63. PubMed ID: 33957183
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing.
Kodjikian L; Arias Barquet L; Papp A; Kertes PJ; Midena E; Ernest J; Silva R; Schmelter T; Niesen T; Leal S
Adv Ther; 2024 Mar; 41(3):1010-1024. PubMed ID: 38183525
[TBL] [Abstract][Full Text] [Related]
10. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
[TBL] [Abstract][Full Text] [Related]
11. Randomized Trial of Biosimilar XSB-001 versus Reference Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
Loewenstein A; Czumbel N; Ernest J; Dusová J; Pearlman J; Nowosielska A
Ophthalmol Retina; 2023 Sep; 7(9):753-761. PubMed ID: 37179017
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
[TBL] [Abstract][Full Text] [Related]
13. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
[TBL] [Abstract][Full Text] [Related]
15. Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW.
Weber M; Dominguez M; Coscas F; Faure C; Baillif S; Kodjikian L; Cohen SY
BMC Ophthalmol; 2020 May; 20(1):206. PubMed ID: 32450838
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial.
Ohji M; Takahashi K; Okada AA; Kobayashi M; Matsuda Y; Terano Y;
Adv Ther; 2020 Mar; 37(3):1173-1187. PubMed ID: 32016788
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration.
Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E
BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.
Heier JS; Wykoff CC; Waheed NK; Kitchens JW; Patel SS; Vitti R; Perlee L; Chu KW; Leal S; Asmus F; Son V; Schmelter T; Brown DM
Ophthalmology; 2020 Feb; 127(2):211-220. PubMed ID: 31791663
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
Khanani AM; Patel SS; Ferrone PJ; Osborne A; Sahni J; Grzeschik S; Basu K; Ehrlich JS; Haskova Z; Dugel PU
JAMA Ophthalmol; 2020 Sep; 138(9):964-972. PubMed ID: 32729897
[TBL] [Abstract][Full Text] [Related]
20. Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
Wykoff CC; Brown DM; Reed K; Berliner AJ; Gerstenblith AT; Breazna A; Abraham P; Fein JG; Chu KW; Clark WL; Leal S; Schmelter T; Hirshberg B; Yancopoulos GD; Vitti R;
JAMA Ophthalmol; 2023 Sep; 141(9):834-842. PubMed ID: 37535382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
